{'fraction_non_alphanumeric': 0.042608695652173914, 'fraction_numerical': 0.050434782608695654, 'mean_word_length': 4.72636815920398, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Influence of Chlorthalidone on the Pharmacokinetics and Pharmacodynamics of Org 10172 (Lomoparan®), A Low Molecular Weight Heparinoid, in Healthy Volunteers

The influence of chlorthalidone (100 mg po) on the pharmacokinetics and pharmacodynamics of Org 10172 (IV bolus injection of 3250 anti‐Xa units), a low molecular weight heparinoid, was studied in six healthy male volunteers using an open randomized two‐way crossover design. Chlorthalidone produced a slight decrease in clearance of anti‐Xa activity from 7.1 ± 1.0 to 6.6 ± 0.8 mL/min and a decrease of the volume of distribution from 0.20 ± 0.05 to 0.16 ± 0.04 L/kg, whereas the volume of distribution of antithrombin activity increased from 0.14 ± 0.05 to 0.26 ± 0.10 L/kg (all differences P <.05). During the entire study period no adverse events occurred. In summary, chlorthalidone showed separate effects on different fractions of Org 10172. The clinical implication of the slight change observed in plasma anti‐Xa activity is likely to be limited, whereas the 80% increase in distribution volume of plasma antithromhin activity can not be defined as yet in terms of clinical relevance.